Effect of glucagon-like peptide-1 receptor agonist in treatment of nonalcoholic fatty liver disease and related mechanism
DOI:10.3969/j.issn.1001-5256.2021.01.043
- VernacularTitle:胰高血糖素样肽1受体激动剂在非酒精性脂肪性肝病治疗中的作用及相关机制
- Author:
Xiaohan YU
1
;
Yulu WANG
;
Xiaoyang XU
;
Jian PING
;
Changqing ZHAO
Author Information
1. Institute of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
- Publication Type:Research Article
- Keywords:
Non-alcoholic Fatty Liver Disease;
Glucagon-Like Peptide-1 Receptor;
Molecular Mechanisms of Pharmacological Action
- From:
Journal of Clinical Hepatology
2021;37(1):196-199
- CountryChina
- Language:Chinese
-
Abstract:
The incidence rate of nonalcoholic fatty liver disease (NAFLD) continues to rise around the world, and due to its complex pathogenesis, there is still a lack of effective treatment drugs. If NAFLD is not treated in time, it may increase the risk of related metabolic diseases such as diabetes and hyperlipidemia and even lead to liver fibrosis and liver cirrhosis. Glucagon-like peptide-1 is a hormone secreted by L-shaped cells of the small intestine and can regulate glucose-dependent stimulation of insulin secretion, reduce gastric emptying, and inhibit food intake. This article reviews the effect of glucagon-like peptide-1 receptor agonist in the treatment of NAFLD and related mechanism.
